On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > COMMENTARY
COMMENTARY
- New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
- Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
- JMA Needs to Establish New Partnership with LDP
April 17, 2006
- COMMENTARY 4 articles
April 3, 2006
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- ＜COMMENTARY＞ New Dispensing Fees Nearly Decided
February 20, 2006
- Japan's Most Admired Pharma Companies P. Reed Maurer
February 20, 2006
- Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
February 13, 2006
- Requirements for External IRBs to Be Relaxed
February 13, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
February 6, 2006
- COMMENTARY 2 articles
January 30, 2006
- JPLA SEMINAR
January 30, 2006
- Maurer's Healthcare Insight (72)
January 30, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -2-
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
January 30, 2006
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…